Gene-Editing Treatment Reduced Cholesterol in Study
A single infusion of CTX310 successfully lowered lipid levels for 12 months in a recent clinical trial.
Updated on Sept. 21, 2026 in Biotech
Live Poll
Do you trust the safety of emerging gene-editing treatments for managing chronic health conditions?
On August 27, 2026, researchers reported that an experimental CRISPR-based gene-editing treatment called CTX310 significantly reduced cholesterol levels. The study, which followed 15 patients for one year, successfully targeted the ANGPTL3 gene to lower blood fats.
Why it matters
The ANGPTL3 gene plays a central role in regulating lipids linked to heart disease, making it a key target for therapies aimed at medication-resistant disorders. This success suggests a new pathway for managing blood fats through permanent genetic adjustment.
The study utilized doses ranging from 0.1 to 0.8 milligrams per kilogram of body weight. The treatment works by delivering CRISPR-Cas9 editing machinery to the liver to switch off the ANGPTL3 gene.
The players
CRISPR Therapeutics AG
This is a gene editing company based in Zug, Switzerland, that funded the research into the CTX310 treatment.
Cleveland Clinic
This medical center served as the primary clinical site for the testing of the gene-editing treatment.
The details
Patients in the study received the treatment via a single infusion after being pretreated with corticosteroids and antihistamines. During the one-year follow-up period, there were no serious adverse events reported that were linked to the therapy.
Timeline
November 2025: Initial clinical trial data was presented.
August 27, 2026: Study results were published in the NEJM.
Next 15 years: Participants will undergo long-term safety monitoring.
The Tech Race
This development represents a shift toward using CRISPR-Cas9 technology to address underlying genetic causes of heart disease rather than managing symptoms with traditional medication. It positions the technology as a potential successor to daily lipid-lowering drugs.
While not yet available for general use, this research suggests a potential future where patients with medication-resistant lipid disorders could achieve long-term cholesterol control with a single infusion. This would eliminate the burden of daily medication adherence for these individuals.
The takeaway
This study demonstrates the potential for single-dose genetic interventions to treat chronic metabolic conditions by permanently silencing specific genes. Future monitoring will be essential to ensure these long-term lipid reductions remain stable and safe over the next 15 years.
Further reading
Learn more about the latest innovations in genetic medicine in the Biotech section.
Live Poll
Do you trust the safety of emerging gene-editing treatments for managing chronic health conditions?
